| |
Pain
|
Mean
|
SE
|
95% CI of the mean
|
P-value
|
95% CI for difference
|
|---|
| | | | |
Lower
|
Upper
| | |
|---|
|
sC2C
|
-
|
5.47
|
0.04
|
5.40
|
5.55
|
0.01*
|
-0.35 to -0.05
|
|
Ln (pmol/ml)
|
+
|
5.67
|
0.06
|
5.55
|
5.79
| | |
|
sCPII
|
-
|
7.28
|
0.07
|
7.14
|
7.43
|
0.03*
|
-0.62 to -0.04
|
|
Ln (ng/ml)
|
+
|
7.62
|
0.12
|
7.37
|
7.86
| | |
|
uCTX-II/Cr
|
-
|
5.14
|
0.12
|
4.90
|
5.38
|
<0.01*
|
-1.30 to -0.34
|
|
Ln (ng/μmol creatinine)
|
+
|
5.96
|
0.20
|
5.56
|
6.37
| | |
|
sC2C/sCPII
|
-
|
0.19
|
0.02
|
0.14
|
0.23
|
0.40
|
-0.05 to 0.13
|
| |
+
|
0.15
|
0.04
|
0.07
|
0.22
| | |
|
uCTX-II/sCPII
|
-
|
0.19
|
0.07
|
0.06
|
0.32
|
0.25
|
-0.42 to 0.12
|
| |
+
|
0.34
|
0.11
|
0.12
|
0.57
| | |
|
uNTx/Cr
|
-
|
3.60
|
0.09
|
3.41
|
6.79
|
0.05*
|
-0.76 to 0.03
|
|
Ln (ng/ml creatinine)
|
+
|
3.98
|
016
|
3.66
|
4.30
| | |
|
sHA
|
-
|
3.03
|
0.12
|
2.78
|
3.28
|
0.04*
|
-1.03 to -0.03
|
|
Ln (pmol/ml)
|
+
|
3.55
|
0.21
|
3.13
|
3.98
| | |
- All analyses were adjusted for age, gender, and body mass index. The urinary biomarkers were corrected for creatinine. The number of subjects with knee pain was 30, while the number without knee pain was 16. *P-values less than or equal to 0.05 are statistically significant.
- 95% CI, 95% confidence interval; C2C, cartilage collagen type II cleavage; CPII, cartilage type II collagen carboxy propeptide; CTX-II, type II collagen C-telopeptide; HA, hyaluronic acid; K/L, Kellgren-Lawrence grade; Ln, natural log; NTx, N-terminal crosslinking telopeptide of type I collagen; s, serum; SE, standard error of the mean; u, urine.
